COMPREHENSIVE ASSESSMENT OF CLINICAL AND IMMUNOLOGICAL PARAMETERS IN THE TREATMENT OF ALLERGIC DERMATOSES WITH BILASTINE MOLECULE

Authors:

Abstract:

One of the most pressing problems in dermatology and venereology is allergic dermatoses. Over recent decades, the incidence of allergic skin diseases has increased significantly. The high prevalence of allergic dermatoses and the insufficient effectiveness of the proposed therapy necessitate the development of new drugs that directly or indirectly affect various stages of the pathological process through their influence on mediator systems. A comprehensive assessment of clinical and immunological indicators was conducted during bilastine treatment of allergic dermatoses. Against the background of bilastine administration, the therapeutic effect in the vast majority of patients began to manifest within the first 4–5 days of treatment. After bilastine use, mild pruritus rated 3–5 points persisted in 16 patients (19.82 %), whereas in 64 patients (79 %) it was observed only periodically and rated 0–2 points. In addition, after bilastine use, 76 patients (93.8 %) reported practically normal sleep (0–2 points), and only 5 patients reported mild sleep disturbances (3–5 points). As a result of complex treatment with bilastine, the absolute and relative numbers of CD4 cells decreased by approximately 30 %, while the number of CD8 cells increased slightly, leading to normalization of the immunoregulatory index, that is, indicators of T-cell immunity. Clinical observations and immunological status assessments in patients with allergic dermatoses confirmed the effectiveness of bilastine and enabled its recommendation as part of the complex therapy for this group of dermatoses.

Keywords:

allergic dermatoses immunoglobulin E bilastine T-cell immunity

References:

1. Alfonso JH, Graff P, Viegas C, Lossius AH, Eriksen E. Hand Eczema, Risk Factors and Microbial Skin Contamination in the Norwegian Waste Sorting Industry: A Cross-Sectional Study. Contact Dermatitis. 2026 Jan;94(1):60-66. doi: 10.1111/cod.70037.
2. Alhabbab RY, Mastronicola D, Lombardi G, Scottà C. TIM3-mediated differentiation of IL-10-producing CD25+ B cells by expanded regulatory T cells. J Mol Med (Berl). 2025 Dec 27;104(1):18. doi: 10.1007/s00109-025-02606-0.
3. Asero R, Calzari P, Vaienti S, Cugno M. Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. Pharmaceuticals (Basel). 2024 Nov 7;17(11):1499. doi: 10.3390/ph17111499.
4. Bousquet J, Grattan CE, Akdis CA, Eigenmann PA, Hoffmann-Sommergruber K, Agache I, et al. Highlights and recent developments in allergic diseases in EAACI journals (2019). Clin Transl Allergy. 2020 Dec 3;10(1):56. doi: 10.1186/s13601-020-00366-3.
5. Bousquet J, Toumi M, Sousa-Pinto B, Anto JM, Bedbrook A, Kaidashev I, et al. The allergic rhinitis and its impact on asthma (ARIA) approach of value-added medicines: as-needed treatment in allergic rhinitis. J Allergy Clin Immunol Pract. 2022 10(11):2878-2888. doi: 10.1016/j.jaip.2022.07.020.
6. Criado PR, Maruta CW, Alchorne AOA, Ramos AMC, Gontijo B, Santos JBD, et al. Consensus on the diagnostic and therapeutic management of chronic spontaneous urticaria in adults - Brazilian Society of Dermatology. An Bras Dermatol. 2019 Apr;94(2 Suppl 1):56-66. doi: 10.1590/abd1806-4841.2019940209.
7. Di Agosta E, Salvati L, Corazza M, Baiardini I, Ambrogio F, Angileri L, et al. Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder. Clin Mol Allergy. 2021 Dec 20;19(1):26. doi: 10.1186/s12948-021-00165-6.
8. Jacques C, Floris I. How an Immune-Factor-Based Formulation of Micro-Immunotherapy Could Interfere with the Physiological Processes Involved in the Atopic March. Int J Mol Sci. 2023 Jan 12;24(2):1483. doi: 10.3390/ijms24021483.
9. Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, et al. Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases. J Allergy Clin Immunol. 2024 Apr;153(4):879-893. doi: 10.1016/j.jaci.2023.08.017.
10. Labib BA, Chigbu DI. Therapeutic Targets in Allergic Conjunctivitis. Pharmaceuticals (Basel). 2022 Apr 28;15(5):547. doi: 10.3390/ph15050547.
11. Sadaba B, Azanza JR, Gomez-Guiu A, Rodil R. Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria. Ther Clin Risk Manag. 2013 9:197-205. doi: 10.2147/TCRM.S16079.
12. Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021 Jun 1;14(6):100533. doi: 10.1016/j.waojou.
13. Seneviratne SL, Jones L, King AS, Black A, Powell S, McMichael AJ, et al. Allergen-specific CD8(+) T cells and atopic disease. J Clin Invest. 2002 Nov;110(9):1283-91. doi: 10.1172/JCI15753.
14. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014 Nov 14;2014(11):CD006137. doi: 10.1002/14651858.
15. Wang J, Zhou Y, Zhang H, Hu L, Liu J, Wang L, et al. Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther. 2023 Mar 24;8(1):138. doi: 10.1038/s41392-023-01344-4.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 46-51
УДК 616-056.3+616.5:615.06-085

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-46-51